**Supplementary Table 1. Adherence to ART during the 12-month follow-up period stratified by US state**

|  |  |  |
| --- | --- | --- |
|  |  | PDC (%) |
|  | **No. of Patients** | **Mean** | **SD** | **Median** | **<80** | **80 to <90** | **≥90** |
| AK | 92 | 67.7 | 26.7 | 73.7 | 55 | 14 | 30 |
| AL | 1,786 | 73.7 | 25.6 | 84.1 | 44 | 21 | 36 |
| AR | 1,213 | 73.2 | 26.9 | 84.7 | 43 | 19 | 38 |
| AZ | 3,635 | 75.2 | 24.3 | 84.9 | 42 | 20 | 37 |
| CA | 10,297 | 77.4 | 24.9 | 88.2 | 36 | 18 | 46 |
| CO | 1,367 | 75.5 | 25.3 | 86.3 | 40 | 20 | 40 |
| CT | 2,623 | 76.5 | 25.0 | 87.4 | 37 | 21 | 42 |
| DC | 2,145 | 69.9 | 27.7 | 79.7 | 50 | 16 | 33 |
| DE | 1,849 | 73.0 | 26.7 | 84.4 | 43 | 20 | 37 |
| FL | 26,067 | 74.6 | 25.9 | 85.8 | 41 | 19 | 40 |
| GA | 8,982 | 73.0 | 25.3 | 82.5 | 46 | 19 | 35 |
| HI | 267 | 79.7 | 24.2 | 89.9 | 34 | 16 | 49 |
| IA | 598 | 72.6 | 27.9 | 85.5 | 43 | 18 | 40 |
| ID | 134 | 77.0 | 24.7 | 87.7 | 37 | 19 | 45 |
| IL | 11,333 | 73.2 | 25.4 | 83.0 | 45 | 19 | 36 |
| IN | 3,369 | 73.5 | 26.3 | 84.4 | 43 | 18 | 38 |
| KS | 564 | 76.4 | 25.0 | 87.9 | 38 | 17 | 45 |
| KY | 1,084 | 70.0 | 29.4 | 82.6 | 46 | 16 | 38 |
| LA | 4,150 | 70.0 | 27.9 | 80.4 | 49 | 18 | 33 |
| MA | 3,503 | 75.7 | 24.3 | 85.8 | 40 | 20 | 40 |
| MD | 7,625 | 70.9 | 26.9 | 81.1 | 48 | 18 | 34 |
| ME | 519 | 71.8 | 27.0 | 84.9 | 47 | 17 | 37 |
| MI | 4,377 | 73.6 | 26.4 | 84.7 | 43 | 19 | 38 |
| MN | 1,659 | 74.6 | 26.4 | 86.6 | 40 | 18 | 42 |
| MO | 3,260 | 77.9 | 23.1 | 87.3 | 36 | 21 | 42 |
| MS | 1,088 | 69.7 | 27.5 | 80.3 | 49 | 17 | 33 |
| MT | 68 | 71.9 | 27.5 | 83.0 | 44 | 18 | 38 |
| NC | 4,695 | 75.2 | 24.9 | 85.8 | 41 | 20 | 39 |
| ND | 95 | 78.3 | 21.2 | 86.8 | 38 | 23 | 39 |
| NE | 657 | 75.9 | 23.9 | 84.9 | 40 | 25 | 35 |
| NH | 344 | 78.9 | 22.3 | 87.8 | 36 | 20 | 44 |
| NJ | 7,606 | 74.6 | 25.7 | 85.5 | 42 | 18 | 40 |
| NM | 569 | 74.7 | 25.1 | 85.8 | 40 | 21 | 39 |
| NV | 2,493 | 74.4 | 24.9 | 84.7 | 43 | 21 | 36 |
| NY | 33,253 | 73.7 | 26.5 | 84.9 | 43 | 19 | 39 |
| OH | 9,127 | 74.7 | 25.3 | 85.5 | 42 | 19 | 39 |
| OK | 1,437 | 77.5 | 23.6 | 87.1 | 37 | 22 | 41 |
| OR | 1,495 | 76.6 | 24.2 | 86.8 | 38 | 19 | 42 |
| PA | 9,408 | 74.7 | 25.9 | 85.8 | 42 | 18 | 40 |
| RI | 337 | 76.6 | 25.5 | 88.5 | 35 | 21 | 45 |
| SC | 2,611 | 72.9 | 26.3 | 83.8 | 44 | 19 | 37 |
| SD | 217 | 83.5 | 21.2 | 92.9 | 25 | 17 | 58 |
| TN | 4,560 | 72.8 | 25.9 | 83.3 | 44 | 20 | 35 |
| TX | 15,081 | 73.3 | 26.2 | 84.4 | 44 | 19 | 38 |
| UT | 371 | 77.8 | 23.9 | 87.9 | 37 | 20 | 43 |
| VA | 4,328 | 71.9 | 27.4 | 83.6 | 45 | 18 | 37 |
| VT | 35 | 76.6 | 26.5 | 88.5 | 40 | 11 | 49 |
| WA | 2,456 | 76.9 | 24.8 | 87.7 | 37 | 20 | 44 |
| WI | 913 | 75.6 | 25.3 | 86.3 | 39 | 18 | 42 |
| WV | 365 | 76.0 | 25.0 | 86.0 | 40 | 19 | 41 |
| WY | 58 | 78.6 | 22.9 | 87.7 | 36 | 21 | 43 |
| Other regions | 309 | 73.2 | 22.2 | 80.3 | 49 | 30 | 21 |

ART: Antiretroviral therapy; PDC: Proportion of days covered. “Other regions” included US territories or military bases not included in the US census regions, etc.

**Supplementary Table 2. Demographic characteristics of study population newlya treated with ART**

|  |  |
| --- | --- |
| **Characteristic** | **N=37,825** |
| **Age (years)** |  |
| Mean (SD) | 44.8 (13.2) |
| Median | 46 |
| **Age group, N %** |   |
| 18-44 years | 17,834 (47.2) |
| 45-54 years | 10,027 (26.5) |
| 55-64 years | 7,696 (20.4) |
| ≥ 65 years | 2,268 (6.0) |
| **Gender, N %** |   |
| Female | 10,686 (28.3) |
| Male | 27,139 (71.8) |
| **Race/ethnicity, N %** |   |
| Caucasian | 9,274 (24.5) |
| Black/African American | 10,292 (27.2) |
| Hispanic | 3,635 (9.6) |
| Asian | 204 (0.5) |
| Unknown/other | 14,420 (38.1) |
| **Insurance type, N %** |   |
| Commercial | 13,637 (36.1) |
| Medicaid | 13,858 (36.6) |
| Medicare | 5,416 (14.3) |
| Other/unspecified | 4,914 (13.0) |
| **US region, N %** |   |
| Midwest | 5,952 (15.7) |
| Northeast | 10,656 (28.2) |
| South | 16,719 (44.2) |
| West | 4,443 (11.8) |
| Other regionsb | 55 (0.2) |

SD: Standard deviation.

a Newly treated, defined as having no ART medication use during

 the 12-month baseline period.

b “Other regions” included US territories or military bases not in the

US census regions, etc.